Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.

@article{Cheong2011DualIO,
  title={Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models.},
  author={Jae-Ho Cheong and Eun Sung Park and Jiyong Liang and Jennifer B. Dennison and Dimitra Tsavachidou and Catherine Nguyen-Charles and Kwai Wa Cheng and Hassan Hall and Dong Zhang and Yiling Lu and Murali K Ravoori and Vikas Kundra and Jaffer Ajani and Ju-seog Lee and Waun Ki Hong and Gordon B. Mills},
  journal={Molecular cancer therapeutics},
  year={2011},
  volume={10 12},
  pages={2350-62}
}
Tumor cell proliferation requires both growth signals and sufficient cellular bioenergetics. The AMP-activated protein kinase (AMPK) pathway seems dominant over the oncogenic signaling pathway suppressing cell proliferation. This study investigated the preclinical efficacy of targeting the tumor bioenergetic pathway using a glycolysis inhibitor 2-deoxyglucose (2DG) and AMPK agonists, AICAR and metformin. We evaluated the in vitro antitumor activity of 2DG, metformin or AICAR alone, and 2DG in… CONTINUE READING